Cargando…

The anti-malarial chloroquine overcomes Primary resistance and restores sensitivity to Trastuzumab in HER2-positive breast cancer

Autophagy may control the de novo refractoriness of HER2 gene-amplified breast carcinomas to the monoclonal antibody trastuzumab (Herceptin). Tumor cells originally obtained from a patient who rapidly progressed on trastuzumab ab initio display increased cellular levels of the LC3-II protein—a findi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cufí, Sílvia, Vazquez-Martin, Alejandro, Oliveras-Ferraros, Cristina, Corominas-Faja, Bruna, Cuyàs, Elisabet, López-Bonet, Eugeni, Martin-Castillo, Begoña, Joven, Jorge, Menendez, Javier A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749547/ https://www.ncbi.nlm.nih.gov/pubmed/23965851 http://dx.doi.org/10.1038/srep02469

Ejemplares similares

Metformin-induced preferential killing of breast cancer initiating CD44(+)CD24(−/low) cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts
por: Cufí, Sílvia, et al.
Publicado: (2012)

Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency
por: Vazquez-Martin, Alejandro, et al.
Publicado: (2012)

Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: Utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment
por: Cufí, Sílvia, et al.
Publicado: (2012)

Mitochondrial fusion by pharmacological manipulation impedes somatic cell reprogramming to pluripotency: New insight into the role of mitophagy in cell stemness
por: Vazquez-Martin, Alejandro, et al.
Publicado: (2012)

Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo
por: Cufí, Sílvia, et al.
Publicado: (2013)

Discovery and validation of an INflammatory PROtein-driven GAstric cancer Signature (INPROGAS) using antibody microarray-based oncoproteomics
por: Puig-Costa, Manuel, et al.
Publicado: (2014)

Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs
por: Corominas-Faja, Bruna, et al.
Publicado: (2012)

Mitophagy-driven mitochondrial rejuvenation regulates stem cell fate
por: Vazquez-Martin, Alejandro, et al.
Publicado: (2016)

Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas
por: Martin-Castillo, Begoña, et al.
Publicado: (2015)

IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations
por: Vazquez-Martin, Alejandro, et al.
Publicado: (2013)

Autophagy Facilitates the Development of Breast Cancer Resistance to the Anti-HER2 Monoclonal Antibody Trastuzumab
por: Vazquez-Martin, Alejandro, et al.
Publicado: (2009)

Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment
por: Menendez, Javier A., et al.
Publicado: (2014)

The nutritional phenome of EMT-induced cancer stem-like cells
por: Cuyàs, Elisabet, et al.
Publicado: (2014)

Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib
por: Oliveras-Ferraros, Cristina, et al.
Publicado: (2011)

Metformin and the ATM DNA damage response (DDR): Accelerating the onset of stress-induced senescence to boost protection against cancer
por: Menendez, Javier A., et al.
Publicado: (2011)

Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched for stem cell-like properties
por: Cuyàs, Elisabet, et al.
Publicado: (2015)

Metabostemness: Metaboloepigenetic reprogramming of cancer stem-cell functions
por: Menendez, Javier A., et al.
Publicado: (2014)

Gerosuppressant Metformin: less is more
por: Menendez, Javier A., et al.
Publicado: (2011)

Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype
por: Cuyàs, Elisabet, et al.
Publicado: (2015)

Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin
por: Cufí, Sílvia, et al.
Publicado: (2013)

Metformin: Multi-faceted protection against cancer
por: Del Barco, Sonia, et al.
Publicado: (2011)

Computer-aided discovery of biological activity spectra for anti-aging and anti-cancer olive oil oleuropeins
por: Corominas-Faja, Bruna, et al.
Publicado: (2014)

BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells
por: Cuyàs, Elisabet, et al.
Publicado: (2017)

Extra-virgin olive oil contains a metabolo-epigenetic inhibitor of cancer stem cells
por: Corominas-Faja, Bruna, et al.
Publicado: (2018)

Chemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells
por: Corominas-Faja, Bruna, et al.
Publicado: (2014)

Oncometabolic Nuclear Reprogramming of Cancer Stemness
por: Menendez, Javier A., et al.
Publicado: (2016)

Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant Basal-HER2 subtype of breast cancer
por: Martin-Castillo, Begoña, et al.
Publicado: (2015)

A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study
por: Martin-Castillo, Begoña, et al.
Publicado: (2018)

Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells
por: Oliveras-Ferraros, C, et al.
Publicado: (2012)

In silico clinical trials for anti-aging therapies
por: Menendez, Javier A., et al.
Publicado: (2019)

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2013)

Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity
por: Verdura, Sara, et al.
Publicado: (2020)

Metabolomic mapping of cancer stem cells for reducing and exploiting tumor heterogeneity
por: Cuyàs, Elisabet, et al.
Publicado: (2017)

Metformin and breast cancer: an opportunity for pharmacogenetics
por: Cuyàs, Elisabet, et al.
Publicado: (2022)

tabAnti-HER2 (erbB-2) oncogene effects of phenolic compounds directly isolated from commercial Extra-Virgin Olive Oil (EVOO)
por: Menendez, Javier A, et al.
Publicado: (2008)

Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance
por: Upton, Rosalynd, et al.
Publicado: (2021)

Suppression of endogenous lipogenesis induces reversion of the malignant phenotype and normalized differentiation in breast cancer
por: Gonzalez-Guerrico, Anatilde M., et al.
Publicado: (2016)

Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It
por: Luque-Cabal, María, et al.
Publicado: (2016)

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
por: Watanabe, Satomi, et al.
Publicado: (2019)

Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy
por: Verdura, Sara, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mdjph30mjmihuppbsdofe1gsa0